Serum Levels of Soluble CD30 (sCD30) in Children 783

A. Merchak,E. Zielińska,A. Giraldo,H. Sawaf,A. Lorenzana
DOI: https://doi.org/10.1203/00006450-199804001-00804
IF: 3.953
1998-04-01
Pediatric Research
Abstract:CD30 is a cytokine receptor that belongs to the TNF/NGF receptor superfamily. It is normally expressed in activated and virus infected T and B cells and possibly monocytes. CD30 is shed in vivo and in vitro; therefore it exists both as membrane bound and soluble forms. High serum levels of sCD30 have been found in EBV infected individuals, adult patients with Hodgkin's disease and CD30 positive lymphomas (CD30+ NHL). The reported normal adult values are 5.3 ± 5.7 u/ml (mean ± SD). No information is available about normal serum levels of this receptor in children or its potential use in children with CD30+ NHL. We sought to establish the values of sCD30 in normal children using a specific ELISA method (Milenia, DPC, Germany). A total of 27 children (19 female, 8 male), age range 6 months to 16 years were studied. The sCD30 serum values ranged from 11 to 230 u/ml with a mean ± SD value of 89.5±83.25. The children were then subdivided into three groups: group 1 included 13 children who presented with normal physical exam, group 2 included 4 children who presented with URI symptoms and group 3 included 10 febrile children. The sCD30 values ranged from 11 to 44 u/ml, 51 to 230 u/ml, 30 to 230 u/ml with mean ± SD values of 28.8±9.5 u/ml, 119±83 u/ml, 156.6±82.9 u/ml for groups 1 to 3 respectively. These differences achieved statistical significance when comparing group 1 with groups 2 and 3 (p value <0.05). We studied 2 additional children with CD30 + NHL (one of them with immunodeficiency). Preliminary results indicate that sCD30 may be a marker of the disease activity. This study shows that sCD30 levels are higher in children when compared with published results in adults and that higher levels can be found in children with infections. These results may be utilized in future studies assessing the role of sCD30 levels in children with infections and CD30+ malignancies.
What problem does this paper attempt to address?